BSH 2019 | CAR-T for ALL: access, eligibility & toxicity

Name: CAR-T for ALL: access, eligibility & toxicity
Uploaded: 2019-04-02T17:45:10.000Z
Duration: 3 min 27 s
Description: Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, discusses the barriers to CAR T-cell therapy for acute lymphoblastic leukemia (ALL) patients. She also explains the patient selection criteria and side effects. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

Sara Ghorashian • 2 Apr 2019

BSH 2019

Acute Lymphoblastic Leukemia Leukemia CAR-T Tocilizumab

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, discusses the barriers to CAR T-cell therapy for acute lymphoblastic leukemia (ALL) patients. She also explains the patient selection criteria and side effects. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.